Showing 1941-1950 of 2836 results for "".
- Allergan Aesthetics Enters Into Option to Acquire Cypris Medicalhttps://modernaesthetics.com/news/allergan-aesthetics-enters-into-option-to-acquire-cypris-medical/2473045/Allergan Aesthetics, an AbbVie company has entered into a warrant agreement with Cypris Medical, a privately held, medical device company based in Chicago. Following the completion of a clinical trial to be initiated in 2021, Allergan Aesthetics will have the right to exercis
- Melasma Update: Studies Show Benefit with Cysperahttps://modernaesthetics.com/news/melasma-update-studies-show-benefit-with-cyspera/2473042/Several studies recently published in peer reviewed journals demonstrate the safety and efficacy of stabilized-cysteamine 5% cream (Cyspera), the novel, non-hydroquinone, topical pigment regulator from Scientis In a randomized, double-blinded study of 50 melasma patients assigned to eit
- Merz and Candela Announce New Collabhttps://modernaesthetics.com/news/merz-and-candela-announce-new-collab/2473041/Merz Aesthetics and Candela Corporation are joining forces. As part of the collab, sales reprentatives from each company will now have the ability to promote products from both organizations. The companies are not formally changing their structure or formally integr
- Managing Employees During the COVID Pandemic: Answers to Top Questionshttps://modernaesthetics.com/news/managing-employees-in-the-covid-pandemic-answers-to-top-questions/2473040/Can I require staff to get a vaccine in order to continue working? In many cases, vaccines can be required, says Josh Alloy, JD, Counsel at Arnold and Porter in Washington, DC, “although there are potential e
- Are COVID-19 Vaccines Risky for Dermal Filler Patients? Dermatologists Weigh the Existing Evidencehttps://modernaesthetics.com/news/are-covid-19-vaccines-risky-for-dermal-filler-patients-dermatologists-weigh-the-existing-evidence/2473039/As case reports of facial swelling in patients with a history of dermal filler treatment who received Moderna’s COVID-19 vaccine accrue, dermatologists are devising new protocols for how to best address this potential phenomenon, including the optimal timing of fillers and vaccines, updated
- Cynosure Hires Katie Cheng As New CMOhttps://modernaesthetics.com/news/cynosure-hires-katie-cheng-as-new-chief-marketing-office/2473038/Katie Cheng is Cynosure’s new Chief Marketing Officer. "Katie's proven track record of consumer and professional marketing strategy and execution is one of the many reasons we are eager to have Katie join our team," says Cynosure CEO Todd Tillemans, i
- Are COVID-19 Vaccines Safe for Filler Patients?https://modernaesthetics.com/news/facial-fillers-and-covid-19-vaccines-is-there-a-risk-for-adverse-reactions/2473036/Three patients with dermal fillers have had adverse reactions to the Moderna COVID-19 vaccine, according to the Aesthetic Society. The FDA intends to note this in its prescribing information. There have been no reported cases in patients receiving the Pfizer COVID-19 vaccine.
- Expert Sets Record Straight on COVID-19 Vaccine/Fillers “Risk”https://modernaesthetics.com/news/expert-sets-record-straight-on-covid-19-vaccinefillers-risk/2473033/When FDA officials reviewed the data for Moderna’s COVID-19 vaccine, a data point garnered some attention. There seemed to be at least a temporal association between treatment with dermal fillers and non-serious adverse reactions to the vaccine in three study subjects. Modern Aesth
- Developing Story: AbbVie’s Allergan Wins Trade Secret Case Against Evolushttps://modernaesthetics.com/news/developing-story-abbvies-allergan-wins-trade-secret-case-against-evolus/2473030/AbbVie Inc.’s Allergan won a U.S. trade agency order to block Evolus Inc. and its partner Daewoong Pharmaceutical Co. from importing Jeuveau into the U.S. for 21 months, according to media reports. The U.S. International Trade Commission upheld a judge’s findings that Jeuvea
- Revance Update: FDA Defers Approval of DaxibotulinumtoxinA Due to COVID-19 Related Travel Restrictions Impacting Manufacturing Site Inspectionhttps://modernaesthetics.com/news/revance-update-fda-defers-approval-of-daxibotulinumtoxina-due-to-covid-19-related-travel-restrictions-impacting-manufacturing-site-inspection/2473027/The U.S. Food and Drug Administration (FDA) deferred a decision on the Biologics License Application (BLA) for Revance’s DaxibotulinumtoxinA for Injection, an investigational neuromodulator product for the treatment of moderate to severe glabellar lines. In a communication r